Products
Sarilumab was approved in the United States and EU in 2017 and in many countries in 2018 as a solution for injection (Kevzara, prefilled syringe, prefilled pen).
Structure and properties
Sarilumab is a human IgG1 monoclonal antibody with a molecular mass of 150 kDa. It is produced by biotechnological methods.
Effects
Sarilumab (ATC L04AC14) has anti-inflammatory and immunosuppressive properties. The effects are based on binding to soluble and membrane-bound interleukin-6 receptors. This blocks the effects of interleukin-6 (IL-6), which is involved in the inflammatory process and the activation of cells of the immune system, among other things. Sarilumab has the same mechanism of action as the humanized antibody tocilizumab (Actemra).
Indications
For the treatment of rheumatoid arthritis.
Dosage
According to the SmPC. The drug is injected subcutaneously.
Contraindications
- Hypersensitivity
- Severe active infections
- Sepsis
- Severe opportunistic infections
For complete precautions, see the drug label.
Adverse effects
The most common potential adverse effects include neutropenia, infection, thrombocytopenia, elevated lipid and transaminase levels, and injection site reactions.
